Our Mission

To discover novel therapeutics that will stop the progression
of neurodegenerative diseases by targeting their underlying causes.

Our Programs

CURRENT CLINICAL TRIALS 

UCB0599 Phase 2 in Patients with Early-stage PD

News

Neuropore Therapies Receives $20 Million (USD) Milestone Payment Under Collaboration and License Agreement with UCB
May 17th, 2021

Neuropore Therapies, Inc. announced today that it has earned a milestone payment related to its collaboration with UCB and the evaluation of UCB0599 for the treatment of Parkinson’s Disease.  

See All News

Events

Neuropore Therapies will be present at BIO Asia International Conference 2020

March 10-11 2020   Tokyo, Japan

See All Events

NPT® Publications

Neuropore publishes paper describing preclinical in vivo characterization of  small molecule targeting α-synuclein as a potential Parkinson's disease therapeutic
November 2nd, 2018

Report in Scientific Reports, describes the beneficial effects of NPT200-11 on multiple disease relevant endpoints in a transgenic mouse model of Parkinson's disease.

See All Publications

 

 

A team poised for success

About Our Team

Our Partners




Corporate

UCB Logo


Foundations & Academic InstitutionsSEE ALL

The Michael J. Fox Foundation for Parkinson's Research
Albert Einstein College of Medicine
University of Sydney

Connect with Neuropore